



## PRIOR AUTHORIZATION WITH STEP THERAPY POLICY

- POLICY:** Wakefulness-Promoting Agents – Wakix Prior Authorization with Step Therapy Policy
- Wakix® (pitolisant tablets – Harmony)

**REVIEW DATE:** 06/11/2025

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

Wakix, an antagonist/inverse agonist of the histamine-3 receptor, is indicated for the following uses:<sup>1</sup>

- **Excessive daytime sleepiness in adults and pediatric patients  $\geq 6$  years of age with narcolepsy.**
- **Cataplexy in adults with narcolepsy.**

Wakix is the only wakefulness-promoting agent that is not a controlled substance.<sup>1-4</sup>

Armodafinil and modafinil are wakefulness-promoting agents with actions similar to sympathomimetic agents (e.g., amphetamine and methylphenidate).<sup>2,3</sup> They are indicated to improve wakefulness in adults with excessive sleepiness associated

with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder. Sunosi® (solriamfetol tablets), a dopamine and norepinephrine reuptake inhibitor, is indicated to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or OSA.<sup>4</sup> Armodafinil, modafinil, and Sunosi are Schedule IV controlled substances.<sup>2-4</sup> Armodafinil, modafinil, and Sunosi are not indicated for the treatment of cataplexy.

Two specialized tests, which can be performed in a sleep disorders clinic, are required to establish a diagnosis of narcolepsy.<sup>7</sup> Polysomnogram is an overnight recording of brain and muscle activity, breathing, and eye movements. The multiple sleep latency test assesses daytime sleepiness by measuring how quickly a person falls asleep and whether they enter rapid eye movement (REM) sleep. On the day after polysomnogram, the patient is asked to take five short naps separated by two hours over the course of a day. If an individual falls asleep in < 8 minutes on average over the five naps, this indicates excessive daytime sleepiness. However, patients with narcolepsy also have an abnormally quick start to REM sleep. If REM sleep happens within 15 minutes at least two times out of the five naps and the sleep study the night before, this is likely an abnormality caused by narcolepsy.

## **Guidelines**

### *Narcolepsy and Cataplexy*

The American Academy of Sleep Medicine (AASM) practice parameters for the treatment of central disorders of hypersomnolence were updated in 2021.<sup>5,6</sup>

- Modafinil, Wakix, Xyrem® (sodium oxybate oral solution), and Sunosi are recommended as effective treatments for daytime sleepiness due to narcolepsy and reducing disease severity in adults (Strong Recommendation for each).
- Wakix and Xyrem have also demonstrated efficacy for the treatment of cataplexy in patients with narcolepsy (Strong Recommendation for each).
- Xyrem and armodafinil have Conditional Recommendations for the treatment of narcolepsy, showing efficacy for daytime sleepiness due to narcolepsy and reducing disease severity.
- Dextroamphetamine has a Conditional Recommendation for the treatment of narcolepsy, showing efficacy for excessive daytime sleepiness and cataplexy.
- Methylphenidate has a Conditional Recommendation for the treatment of narcolepsy, showing efficacy in reducing disease severity.
- There was insufficient and inconclusive evidence to make recommendations for l-carnitine, scheduled naps, selegiline, triazolam, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors.
- Modafinil and Xyrem have Conditional Recommendations for the treatment of narcolepsy in pediatric patients.

Note: A Strong Recommendation should be followed by clinicians under most circumstances. A Conditional Recommendation requires that the clinician use clinical knowledge and experience and strongly consider the individual patient's values and preferences to determine the best course of action.

## **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Wakix. This Prior Authorization Policy also contains a Step Therapy component. When clinically appropriate, the patient is directed to try one Step 1 Product (dextroamphetamine for cataplexy in narcolepsy; modafinil or armodafinil for excessive daytime sleepiness in narcolepsy) prior to Wakix (Step 2). All approvals are provided for the duration noted below.

• **Wakix® (pitolisant tablets – Harmony)**  
**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

### **FDA-Approved Indications**

- 1. Cataplexy Treatment in a Patient with Narcolepsy.** Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):
  - A)** Patient is  $\geq 18$  years of age; AND
  - B)** Patient has been evaluated using polysomnography and a multiple sleep latency test; AND
  - C)** According to the prescriber, diagnosis of narcolepsy has been confirmed; AND
  - D)** The medication is prescribed by or in consultation with a sleep specialist physician or a neurologist; AND
  - E)** Patient meets ONE of the following (i or ii):
    - i.** Patient has tried dextroamphetamine; OR
    - ii.** According to the prescriber, patient has a contraindication or intolerance to dextroamphetamine.  
Note: Contraindications to dextroamphetamine include a history of substance use disorder; advanced arteriosclerosis, symptomatic cardiovascular disease, and/or moderate to severe hypertension; hyperthyroidism; known hypersensitivity to sympathomimetic amines; glaucoma; agitated states; concomitant administration with monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs.
- 2. Excessive Daytime Sleepiness Associated with Narcolepsy.** Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):
  - A)** Patient is  $\geq 6$  years of age; AND
  - B)** Patient has been evaluated using polysomnography and a multiple sleep latency test; AND
  - C)** According to the prescriber, diagnosis of narcolepsy has been confirmed; AND
  - D)** The medication is prescribed by or in consultation with a sleep specialist physician or a neurologist; AND
  - E)** Patient meets ONE of the following (i or ii):

- i. Patient has tried at least ONE of the following treatments: a central nervous system (CNS) stimulant, generic modafinil, or generic armodafinil; OR  
Note: Examples of CNS stimulants include methylphenidate, dexamethylphenidate, and dextroamphetamine. An exception to this requirement is allowed if the patient has previously tried brand Provigil or brand Nuvigil.
- ii. According to the prescriber, patient has a history of substance use disorder and a wakefulness-promoting agent that is not a controlled substance is necessary.

## CONDITIONS NOT COVERED

- **Wakix® (pitolisant tablets – Harmony)**  
**is(are) considered not medically necessary for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):**

1. **Concomitant Use of Wakix with an Oxybate Product and/or Sunosi (solriamfetol tablets).** Wakix, an antagonist/inverse agonist of the histamine-3 receptor, is indicated for excessive daytime sleepiness and cataplexy in adults with narcolepsy.<sup>1</sup> Oxybate products include Xyrem (sodium oxybate oral solution), Lumryz (sodium oxybate extended-release oral suspension), and Xywav (calcium, magnesium, potassium, and sodium oxybates oral solution).<sup>8-10</sup> These products have the same active ingredient (oxybate, a central nervous system depressant) and have not been studied for use in combination or as alternating treatments. Sunosi, a dopamine and norepinephrine reuptake inhibitor, is indicated to improve wakefulness in adults with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea.<sup>2</sup> Currently, there are no published studies evaluating combination use of these medications.

## REFERENCES

1. Wakix® tablets [prescribing information]. Plymouth Meeting, PA: Harmony Biosciences; May 2025.
2. Sunosi® tablets [prescribing information]. New York, NY: Axsome; June 2023.
3. Provigil® tablets [prescribing information]. Parsippany, NJ: Teva; December 2022.
4. Nuvigil® tablets [prescribing information]. Parsippany, NJ: Teva; December 2022.
5. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2021;17(9):1881–1893.
6. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. *J Clin Sleep Med*. 2021;17(9):1895–1945.
7. National Institutes of Health. Narcolepsy. National Institute of Neurological Disorders and Stroke. Last reviewed on January 10, 2025. Available at: [Narcolepsy | National Institute of Neurological Disorders and Stroke \(nih.gov\)](https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Patient-Education/Fact-Sheets/Narcolepsy). Accessed on June 9, 2025.

8. Xyrem® oral solution [prescribing information]. Palo Alto, CA: Jazz; April 2023.
9. Lumryz™ extended-release oral suspension [prescribing information]. Chesterfield, MO: Avadel; October 2024.
10. Xywav® oral solution [prescribing information]. Palo Alto, CA: Jazz; April 2023.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	<b>Conditions Not Covered:</b> Concomitant use of Wakix with Xyrem (sodium oxybate oral solution), Xywav (calcium, magnesium, potassium, and sodium oxybates oral solution), and/or Sunosi (solriamfetol tablets) was changed to Concomitant use of Wakix with an oxybate product and/or Sunosi (solriamfetol tablets). This change was made due to the availability of a new oxybate product, Lumryz (sodium oxybate extended-release oral suspension). Xyrem, Xywav, and Lumryz are now detailed in the following paragraph.	09/20/2023
Early Annual Revision	<b>Excessive Daytime Sleepiness Associated with Narcolepsy:</b> Wakix is now indicated for use in adults and pediatric patients $\geq 6$ years of age; therefore, the age for approval was changed to $\geq 6$ years of age. Because modafinil and armodafinil are only approved for use in adults, the step component now includes the qualifier "If the patient is $\geq 18$ years of age".	7/3/2024
Selected Revision	<b>Excessive Daytime Sleepiness Associated with Narcolepsy.</b> The criteria were updated to include central nervous system (CNS) stimulants as an option for patients who are $\geq 18$ years of age to have tried prior to approval of Wakix. Now a patient who is $\geq 18$ years of age needs to have tried a CNS stimulant, generic modafinil, or generic armodafinil OR have a history of substance use disorder prior to approval of Wakix. Previously, a patient who is $\geq 18$ years of age had to have tried one of generic modafinil or generic armodafinil OR have a history of substance use disorder. Additionally, examples CNS stimulants were added to the Note.	09/04/2024
Selected Revision	<b>Excessive Daytime Sleepiness Associated with Narcolepsy.</b> The criteria were updated to remove the restriction to patients who are $\geq 18$ years of age when requiring a patient to have tried a central nervous system (CNS) stimulant, generic modafinil, or generic armodafinil OR have a history of substance use disorder prior to approval of Wakix.	11/20/2024
Annual Revision	No criteria changes.	06/11/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.